文献速递妇科

非子宫内膜样子宫内膜癌中与淋巴结受累风险相关的原发肿瘤病理因素

Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2022-02-23

该研究基于美国国家癌症数据库2004至2016年间接受初次手术且至少采样1枚淋巴结的病理T1-T2期癌肉瘤、透明细胞癌、子宫乳头状浆液性癌(UPSC)及混合组织学类型子宫内膜癌患者11390例,其中1950例(18%)淋巴结阳性。多因素分析显示病理肿瘤分期增高、肿瘤体积每增加1厘米及存在淋巴血管侵犯(LVI)可预测总体淋巴结阳性,透明细胞癌和UPSC较癌肉瘤淋巴结阳性风险更高,混合组织学类型无显著差异。

要点

  • 病理T2期较pT1a期淋巴结阳性风险增高(OR 3.63,95%CI 3.15-4.18,p<0.001)。
  • 肿瘤每增大1厘米淋巴结阳性风险增高(OR 1.08,95%CI 1.06-1.10,p<0.001)。
  • 存在淋巴血管侵犯预测淋巴结阳性(OR 4.97,95%CI 4.43-5.57,p<0.001)。

核心结论

  • 在非子宫内膜样子宫内膜癌患者中,淋巴结阳性的预测因素与子宫内膜腺癌相似。
  • 所构建的列线图可能有助于为这些较少见组织学类型制定辅助治疗决策。

研究设计与样本

  • 研究纳入美国国家癌症数据库中2004至2016年间诊断为病理T1-T2期癌肉瘤、透明细胞癌、子宫乳头状浆液性癌(UPSC)和混合组织学类型子宫内膜癌、接受初次手术且至少采样1枚淋巴结的患者。
  • 共纳入11390例患者,其中1950例(18%)淋巴结阳性;采用逻辑回归识别原发病理肿瘤预测因素,并构建列线图预测总体、仅盆腔及腹主动脉旁伴或不伴盆腔淋巴结受累。

主要发现

  • 多因素分析中,病理肿瘤分期增高(pT2 vs pT1a,OR 3.63,95%CI 3.15-4.18,p<0.001)、肿瘤每增大1厘米(OR 1.08,95%CI 1.06-1.10,p<0.001)及存在淋巴血管侵犯(LVI)(OR 4.97,95%CI 4.43-5.57,p<0.001)可预测总体淋巴结阳性。
  • 相对于癌肉瘤,透明细胞癌(OR 1.54,95%CI 1.22-1.95,p<0.001)和UPSC(OR 1.73,95%CI 1.48-2.02,p<0.001)组织学类型与更高的淋巴结阳性风险显著相关。
  • 混合组织学类型与淋巴结阳性风险无显著关联(OR 1.07,95%CI 0.92-1.24,p=0.42)。

关键数值与推荐

  • pT2 vs pT1a:OR 3.63,95%CI 3.15-4.18,p<0.001。
  • 肿瘤每增大1厘米:OR 1.08,95%CI 1.06-1.10,p<0.001。
  • 存在淋巴血管侵犯(LVI):OR 4.97,95%CI 4.43-5.57,p<0.001。
  • 透明细胞癌 vs 癌肉瘤:OR 1.54,95%CI 1.22-1.95,p<0.001。
  • UPSC vs 癌肉瘤:OR 1.73,95%CI 1.48-2.02,p<0.001;混合组织学类型 vs 癌肉瘤:OR 1.07,95%CI 0.92-1.24,p=0.42。

临床怎么用

  • 作者认为,所构建的列线图可能有助于为这些较少见组织学类型制定辅助治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: Lymph node (LN) involvement is an important factor in guiding adjuvant treatment for patients with endometrial cancer. Risk factors for LN involvement are fairly well-established for endometrial adenocarcinoma, but it is not as well defined whether these factors similarly predict LN positivity in less common histologies. MATERIALS/METHODS: Patients diagnosed with pathologic T1-T2 carcinosarcoma, clear cell, uterine papillary serous carcinoma (UPSC), and mixed histologic type endometrial cancer between 2004 and 2016 undergoing primary surgery with at least 1 lymph node sampled in the National Cancer Data Base were identified. Logistic regression was performed to identify primary pathologic tumor predictors of LN positivity. Nomograms were created to predict overall, pelvic only, and paraaortic with or without pelvic LN involvement. RESULTS: Among 11,390 patients included, 1950 (18%) were node positive. On multivariable analysis, increasing pathologic tumor stage (pT2 versus pT1a, odds ratio [OR] 3.63, 95% confidence interval [CI] 3.15-4.18, p < 0.001), increase in tumor size per centimeter (OR 1.08, 95% CI 1.06-1.10, p < 0.001), and the presence of lymphovascular invasion (LVI) (OR 4.97, 95% CI 4.43-5.57, p < 0.001) were predictive of overall LN positivity. Relative to carcinosarcoma, both clear cell (OR 1.54, 95% CI 1.22-1.95, p < 0.001) and UPSC (OR 1.73, 95% CI 1.48-2.02, p < 0.001) histology were significantly associated with a higher risk of LN positivity while mixed histology was not (OR 1.07, 95% CI 0.92-1.24, p = 0.42). CONCLUSION: Among patients with non-endometrioid endometrial cancer, predictors of LN positivity are similar to endometrial adenocarcinoma. The nomograms provided could be helpful in making adjuvant treatment decisions for these less common histologies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Anderson EM, Luu M, Lu DJ, et al. Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. Gynecol Oncol. 2022. PMID: 35216809. doi:10.1016/j.ygyno.2022.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。